EN DE

Nissan Medical Industries Ltd (NISA) Fair Value & Analysis

Healthcare · Il · Market cap 71.1M ILA

NM Nissan Medical Industries Ltd NISA · TA
Price8.20 ILA
Fair Value11.58 ILA
Upside+41.2%
Quality46/100
Watch Nissan Medical Industries Ltd for free, get notified when fair value or trend changes. Watch for free
Weak Growth
Thin margins · 0.6% net margin
Low debt · generates free cash flow
0.23% dividend yield
Mixed vs. peers (6/14)
Narrow moat 25/100
Evidence: Medium Range 11.58 ILA – 11.58 ILA Share as image

Fair value as of: Jul 16, 2026

From 24 valuation models · updated 25 days ago

Share price +5.6% over the past month.

Below-average quality, screening 41% undervalued on our models.

What matters now

  • The price is below even our cautious bear case (11.58 ILA). The market is more pessimistic than our downside scenario.
  • Solid quality (46/100) at a price below fair value, the discount is the argument here, not the business quality.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

24.06 ILA 5.89 ILA Fair Value 11.58 ILA Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 16, 2026.

How to read this chart

60‑month range 5.89 ILA – 24.06 ILA · the 8.20 ILA price screens below the 11.58 ILA fair value. Dashed = 300-day average. As of Jul 16, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Nissan Medical Industries Ltd (NISA) currently trades at 8.20 ILA, while our model-based Fair Value estimate is 11.58 ILA, implying the stock looks roughly 41.2% undervalued today. The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Over the trailing twelve months, Nissan Medical Industries Ltd generated revenue of 652M ILA at a net margin of 0.6%. Revenue grew 8.1% year over year. It earns a return on equity of 2.6%. Net debt stands at 172M ILA. Fundamentals as of Jul 16, 2026

For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 41%, NISA screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 18.72 ILA 23.46 ILA 29.54 ILA 80
Residual Income 13.70 ILA 12.88 ILA 9.05 ILA 76
Rev-Margin DCF 18.36 ILA 27.26 ILA 37.43 ILA 74
All 24 models by family
DCF Models
FCF DCF 18.38 ILA 23.48 ILA 30.42 ILA 38
Owner Earnings 0.5800 ILA 1.20 ILA 2.04 ILA 31
5Y Revenue Exit 18.36 ILA 26.85 ILA 38.03 ILA 39
5Y EBITDA Exit 32.61 ILA 51.42 ILA 73.97 ILA 41
5Y P/E Exit 10.99 ILA 14.16 ILA 17.54 ILA 38
10Y Revenue Exit 17.75 ILA 24.45 ILA 32.17 ILA 36
10Y EBITDA Exit 25.73 ILA 38.41 ILA 53.29 ILA 37
10Y P/E Exit 14.30 ILA 17.24 ILA 20.12 ILA 35
Earnings-Based
Graham-Dodd 3.12 ILA 5.97 ILA 7.45 ILA 54
EPV 13.53 ILA 15.38 ILA 16.88 ILA 59
Dividend Discount
Gordon GGM 12.68 ILA 16.07 ILA 19.00 ILA 70
DDM Multi-Stage 12.68 ILA 16.16 ILA 19.52 ILA 61
Multiples
P/E Multiple 7.58 ILA 10.11 ILA 12.63 ILA 63
P/S Multiple 5.86 ILA 7.81 ILA 9.76 ILA 58
P/B Multiple 5.86 ILA 7.81 ILA 9.76 ILA 55
EV/EBIT 28.67 ILA 38.85 ILA 49.04 ILA 53
EV/EBITDA 52.04 ILA 70.01 ILA 87.98 ILA 54
EV/Revenue 19.93 ILA 29.27 ILA 38.61 ILA 43
Asset-Based
NCAV (Graham) 10.66 ILA 14.29 ILA 21.32 ILA 50
Growth DCF
Growth DCF 18.72 ILA 23.46 ILA 29.54 ILA 80
Rev-Margin DCF 18.36 ILA 27.26 ILA 37.43 ILA 74
Economic Profit
Residual Income 13.70 ILA 12.88 ILA 9.05 ILA 76
ROIC Compounder 13.53 ILA 15.38 ILA 16.88 ILA 72
Growth Earnings
Growth-Adj P/E 5.42 ILA 7.75 ILA 10.07 ILA 68

Widest divergence: DCF Models (23.48 ILA) versus Earnings-Based (5.97 ILA). Highest evidence: Growth DCF (80).

Notify me when NISA reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 652M ILA
Revenue growth (YoY) +8.1%
Net margin 0.6%
Return on equity 2.6%
Free cash flow 24.2M ILA FY2025
P/E ratio 16.0
More key figures
Operating margin 7.1%
EPS (TTM) 0.4300 ILA
EPS growth (YoY) +6,844%
Net debt 172M ILA FY2025

Figures from reported company fundamentals · as of Jul 16, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 46/100

Of which business quality 45 · Market factors (momentum, volatility) 48

Profitability 33
Margins and returns on capital today
Quality Growth 45
Are margins and returns improving?
Cashflow 47
Earnings quality: real cash, not paper profit
Fin. Strength 29
Balance sheet, leverage, solvency risk
Investment 96
Disciplined investing over empire-building
Low Volatility 87
Calm price path (market factor)
Momentum 30
Price trend over the last 3–12 months (market factor)
52W Momentum 32
Distance to the 52-week high (market factor)
Net Issuance 42
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Nissan Medical Industries Ltd manufactures and markets spunlace non-woven fabrics in the United States, Canada, Europe, the Far East, Israel, and internationally. Its products are used in reusable and consumable consumer products, medical products, automotive, infrastructure, hygienic, and other industries.

Full company description

Nissan Medical Industries Ltd manufactures and markets spunlace non-woven fabrics in the United States, Canada, Europe, the Far East, Israel, and internationally. Its products are used in reusable and consumable consumer products, medical products, automotive, infrastructure, hygienic, and other industries. The company sells its products through its sales agents. Nissan Medical Industries Ltd was incorporated in 1984 and is based in Tel Aviv-Yafo, Israel.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Nissan Medical Industries Ltd reported revenue of 652M ILA in FY2025 versus 668M ILA in FY2021, a compound −0.6%/yr. Reported net income was 4.2M ILA in FY2025, compounding −41.7%/yr from FY2021.

Growth Quality 40/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
652M ILS
Latest YoY
−1.9%
Avg. growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−1.6%
Avg. growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−2.0%
Avg. growth/yr (18Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+3.0%
Revenue −0.6%/yr
FY21 668M ILA
FY22 685M ILA
FY23 734M ILA
FY24 664M ILA
FY25 652M ILA
Net income −41.7%/yr
FY21 36.0M ILA
FY22 −36.0M ILA
FY23 5.6M ILA
FY24 7.9M ILA
FY25 4.2M ILA
Character of growth · EPS growth decomposed (2014-2025) −9.9 % p.a.
Revenue per share +5.5 pp

of which total revenue +3.1 pp · buybacks/dilution +2.4 pp

EBIT margin −9.4 pp
Tax rate +0.8 pp
Residual (interest, one-offs) −6.8 pp

Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).

Watch NISA: get an alert when its fair value changes →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Nissan Medical Industries Ltd · Fair Value
11.58 ILA +41%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Nissan Medical Industries Ltd Fair Value". https://www.fairvalue-calculator.com/stock/NISA

Peer Group

Medical Instruments & Supplies · 203 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 46 · Below median
Fair Value upside +41% · Top 25%
Return on equity (TTM) 3% · Below median
Return on assets 2% · Below median
Net margin (TTM) 1% · Below median
Operating margin (TTM) -2% · Bottom 25%
Revenue growth -8% · Bottom 25%
Dividend yield (TTM) 0.2% · Bottom 25%
Debt / equity 0.18× · Higher than median

Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper

P/E (TTM) 18.2× · Cheaper than median
P/B 0.12× · Cheaper than 75% of peers
P/S (TTM) 0.04× · Cheaper than 75% of peers
P/FCF 1.0× · Cheaper than 75% of peers
EV/EBITDA 0.9× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 88 · sector 0
FUTURE 0 · sector 27
PAST 10 · sector 25
HEALTH 91 · sector 96
DIVIDEND 5 · sector 32

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).

Stock Price Fair Value vs Fair Value
Intuitive Surgical, Inc ISRG $402.33 $150.04 -63%
EssilorLuxottica Société anonyme 1EL €172.45 €68.55 -60%
Medline Inc MDLN $41.11 $30.15 -27%
Becton, Dickinson and Company BDX $150.65 $103.53 -31%
Alcon Inc ALC $70.26 $39.78 -43%
ResMed Inc RMD $203.87 $187.89 -8%
West Pharmaceutical Services, Inc WST $353.71 $143.97 -59%
Straumann Holding STMN CHF 106.00 CHF 47.31 -55%
Sartorius Stedim Biotech S.A DIM €188.50 €51.16 -73%
Coloplast A/S COLOB kr 414.00 kr 382.22 -8%

Compare Nissan Medical Industries Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Nissan Medical Industries Ltd (NISA) overvalued or undervalued?
As of Jul 16, 2026, our model estimates a fair value of 11.58 ILA versus a price of 8.20 ILA, about +41% (undervalued).
What is the fair value of NISA?
Our model-based fair value for Nissan Medical Industries Ltd is 11.58 ILA (as of Jul 16, 2026), built from audited fundamentals. The current price is 8.20 ILA.
What is the quality score of NISA?
Nissan Medical Industries Ltd has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Nissan Medical Industries Ltd (NISA)?
Nissan Medical Industries Ltd reported trailing-twelve-month revenue of about 652M ILS (latest available figure, as of Jul 16, 2026).
What is the net profit margin of NISA?
The net profit margin of Nissan Medical Industries Ltd is about 0.6%, meaning it keeps roughly 0.6% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Nissan Medical Industries Ltd and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.